Enovis Corporation (ENOV) AI Stock Analysis

Enovis Corporation operates globally as a medical technology company specializing in the development, manufacturing, and distribution of medical devices. Its products treat musculoskeletal conditions stemming from degenerative diseases, deformities, trauma, and sports injuries. The portfolio includes rigid and soft orthopedic bracings, hot and cold therapy systems, bone growth stimulators, vascular therapy systems, compression garments, therapeutic shoes, inserts, electrical stimulators, and reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger. Enovis markets via independent distributors, consumer retail stores, pharmacies, and directly under the DJO brand.

Revenue expanded from $1.43B in FY2021 to $2.25B in FY2025, though 5-year revenue CAGR from FY2020 to FY2025 was -6.0%. Gross margin rose to 59.8% in FY2025 from 54.5% in FY2021. However, profitability has remained pressured; operating margin was -0.8% in FY2025, and net income was -$1.18B, reflecting a net margin of -52.7%. For the trailing twelve months, revenue was $2.30B with an operating margin of 4.2% and EPS of -$19.23. In the latest quarter ended June 30, 2026, quarterly revenue grew 3.2% year-over-year, while quarterly earnings grew 153.1%.

As of June 30, 2026, Enovis held $12.6M in cash and short-term investments against total debt of $1.37B, resulting in net debt of $1.36B. Debt-to-equity stood at 0.93, while the current ratio was 1.98. In FY2025, operating cash flow reached $217.3M and free cash flow was $19.9M, after deducting capital expenditures of $197.4M. Over the past five years, the company's share count declined 9.4%.

Enovis traded at $19.59 on October 16, 2026, giving it a market cap of $1.13B and enterprise value of $2.41B. The stock trades at a forward P/E of 4.6x and price-to-sales of 0.5x, compared to medians of 17.3x and 4.1x, respectively, for its US-listed Healthcare peers. Its EV/EBITDA stands at 22.4x versus the peer median of 12.0x. Over the past year, Enovis shares fell 37.2%, underperforming the S&P 500 (SPY), which gained 16.8%.

Wall Street coverage includes 10 Strong Buy, 2 Buy, and 1 Hold ratings, with no Sell or Strong Sell recommendations. The mean price target is $36.08, representing 84.2% upside from the last close of $19.59. For the fiscal year ending December 31, 2026, analysts expect revenue of $2.34B and EPS of $3.63. For the following fiscal year, 13 analysts project revenue of $2.45B and EPS of $3.54. Enovis beat EPS estimates in 3 of the last 4 quarters, with next earnings scheduled for November 5, 2026.

This page is an AI-written research summary of Enovis Corporation (ENOV). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ENOV income statement, ENOV balance sheet, ENOV key metrics, ENOV analyst forecast, ENOV chart. See the ENOV stock overview for the latest quote and news.